Targeted Protein Degradation (TPD) Technology Platform

Targeted protein degradation (TPD) represents a transformative approach in drug discovery and development. Central to TPD's efficacy is its ability to exploit the ubiquitin-proteasome system (UPS), a natural pathway cells use to maintain protein homeostasis. By leveraging synthetic molecules such as proteolysis targeting chimeras (PROTACs) and molecular glues, researchers can redirect E3 ligases to degrade specific proteins of interest. Unlike traditional small-molecule inhibitors that bind and block the activity of disease-related proteins, TPD employs the cell's own protein degradation machinery to selectively eliminate unwanted or dysfunctional proteins. This paradigm-shifting technology provides opportunities to tackle previously "undruggable" targets and offers a broad spectrum of applications in oncology, neurodegenerative diseases, and beyond. Therefore, the concept of targeted degradation is gaining traction in the pharmaceutical industry, with numerous companies investing in the development of TPD to address complex diseases more effectively. At our company, we have built a comprehensive TPD technology platform designed to selectively target and eradicate pathogenic proteins.

Our Targeted Protein Degradation (TPD) Technology Platform

Our platform specializes in developing novel E3 ligases, as well as small molecules known as PROTACs and molecular glues.

E3 Ligases Research Platform

At the heart of targeted protein degradation is the E3 ligase, an enzyme that tags target proteins with ubiquitin molecules for subsequent degradation by the proteasome. Our E3 ligases research platform is designed to identify and utilize disease-associated E3 ligases, as well as to further design effective binders.

Learn More

Molecular Glue Discovery Platform

Molecular glues represent a class of small molecules that stabilize interactions between a target protein and an E3 ligase, leading to targeted protein degradation. Our molecular glue discovery platform is dedicated to identifying, developing and optimizing these small molecules through our multiple capabilities such as unique molecular glue compound library, advanced screening techniques, comprehensive biophysical and cellular assays, advanced artificial intelligence technology, etc.

Learn More

PROTACs Development Platform

PROTACs are heterobifunctional molecules that bring a target protein into close proximity with an E3 ligase, facilitating its ubiquitination and degradation. Our PROTAC development platform offers end-to-end capabilities in designing, synthesizing, and optimizing PROTACs.

Learn More

Benefits of Targeted Protein Degradation

The advantages of targeted protein degradation over traditional therapeutic approaches are manifold.

• Firstly, TPD provides the ability to target proteins that lack enzymatic activity or are present in complex multi-protein structures that are not amenable to inhibition by conventional small molecules. This expands the druggable proteome, allowing researchers to tackle a broader spectrum of diseases.
• Secondly, TPD offers the potential for more durable therapeutic effects. By completely removing the disease-driving proteins, TPD can ensure a prolonged therapeutic outcome and potentially lower the risk of drug resistance that often occurs with traditional inhibitors that merely suppress protein activity.
• Another key benefit is the possibility of reducing off-target effects and improving safety profiles. Unlike small molecule inhibitors that often interact with multiple proteins, degraders can be specifically tailored to engage only the intended target, minimizing unintended interactions and reducing adverse side effects.
• Moreover, TPD platforms have demonstrated the ability to reprogram cellular signaling pathways in a way that small molecule inhibitors cannot. By eliminating key regulatory proteins, TPD has the potential to modulate complex biological networks, providing new therapeutic strategies for multifactorial diseases.

The targeted protein degradation technology platform offers a revolutionary approach to modern drug discovery, unlocking the potential to address complex and challenging diseases. Our integrated platform, spanning E3 ligase research, molecular glue discovery, and PROTACs development, aims to deliver transformative therapies. For more information, please feel free to contact us.

It should be noted that our service is only used for research, not for clinical use.